Mperia Therapeutics Adds Experts in Drug Delivery, Dry AMD & Atherosclerosis to CAB

MONTREAL–(BUSINESS WIRE)–CEO President Paul Chipperton is pleased to announce today the
appointment of Dr Daniel Saban, PhD; Dr Szilard Voros PhD, MD; and Dr
Jean-Christophe Leroux, PhD; to the company’s Clinical Advisory Board
(CAB). He commented “all three bring complementary applied
Ophthalmology, Cardiovascular, and Drug Delivery expertise respectively
to the clinical development of our CD36 receptor drug candidates. They
will join our scientific founder Dr Huy Ong in accelerating our
programs.”

Dr. Saban, PhD is an Associate Professor of Ophthalmology and
Immunology at Duke University. He received his PhD from the University
of Florida in Immunological Sciences, and completed his postdoctoral
fellowship at Harvard Medical School, Mass. Eye and Ear Infirmary in
Ocular Immunology. Currently, Dr. Saban serves as Scientific Director of
the Foster Center for Ocular Immunology at the Duke Eye Center, as well
as the co-Director of the Neuroimmunology and Glia Group at the Duke
Institute for Brain Sciences, and is a member of the Annual Meeting
Programs Committee for the Immunology and Microbiology section for the
Association for Research in Vision and Ophthalmology (ARVO). Dr. Saban’s
lab studies the role of myeloid cells in the context of eye and retinal
disease (Reyes et al, Nature Reviews Immunology. 2017). His
lab recently discovered (Reyes et al, Science Translational
Medicine
. 2018) a role for neutrophils in driving Meibomian gland
dysfunction (MGD), the leading cause of Dry Eye Disease.

Dr. Voros, PhD, MD is a trained cardiologist and geneticist,
formerly as Chief of Cardiovascular Prevention and Medical Director of
Cardiovascular Imaging at Piedmont Heart Institute, Atlanta.
Subsequently he founded and became CEO of Global Genomics Group (“G3”),
a precision-medicine-based biotechnology company, developing and
commercializing diagnostic biomarkers and novel drug targets for common
diseases. G3 has developed a diagnostic blood test for cardiovascular
disease and has identified several novel drug targets. He has published
extensively in major scientific journals including: Nature
Reviews, New England Journal of Medicine, Annals of Internal Medicine,
Journal of the American College of Cardiology 
and Circulation:
Cardiovascular Genetics
.

“I am very enthusiastic about exploring the therapeutic modulation of
the CD36 pathway to impact major unmet medical needs such as dry AMD,
atherosclerotic heart disease and fatty liver disease. The CD36 pathway
uniquely sits at the intersection of lipid metabolism, innate immunity
and inflammation, opening the opportunity to modulate a number of
disease conditions where these pathways are dysregulated. Mperia
Therapeutics has a pipeline of compounds in development to modulate the
CD36 pathway and I am keen to see much needed therapeutic solutions
delivered to patients as a result of this program,” said Dr Voros.

Dr Leroux, PhD is the Chairman of Mperia Therapeutics’
CAB. He has significant therapeutic development experience as the
co-founder and SAB member of current Switzerland-based start-up
companies: Versantis AG and Inositec AG. His research interests include
the design of novel biopolymers, drug delivery systems, the targeting of
anti-cancer drugs and formulation of peptidic molecules. After spending
more than ten years as Professor at the University of Montreal, Pharmacy
School, he crossed the Atlantic in 2008 to accept an appointment of Full
Professor at ETH Zurich. Dr Leroux published more than 200 peer-reviewed
scientific papers in international journals and supervised about 70
combined Ph.D. students and postdoctoral trainees.

ABOUT MPERIA THERAPEUTICS

Mperia Therapeutics is the CD36 Therapeutics Company which focuses on
macrophage-driven inflammation. The technology basis resides in highly
specific CD36 receptor cyclic peptides which modulate the inflammasome
in addition to modifying macrophages’ metabolic dysfunction with
outstanding anti-inflammatory response. Mperia holds exclusive rights to
various highly efficacious CD36 receptors ligands against dAMD and
atherosclerosis.

الموقع يستعمل RSS Poster بدعم القاهرة اليوم